The use of IHC to assess the ER and PR status of breast cancers in formalin-fixed, paraffin-embedded (FFPE) tissue sections of cancer samples is now a routine part of pathology practice worldwide and is recommended to be performed in all primary invasive breast carcinomas and on recurrent or metastatic tumors. This evidence concerns the gene ESR1 and breast carcinoma.